Immunovant Inc (IMVT) concluded trading on Wednesday at a closing price of $18.88, with 9.23 million shares of worth about $174.27 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -35.85% during that period and on Wednesday the price saw a gain of about 0.48%. Currently the company’s common shares owned by public are about 147.20M shares, out of which, 69.37M shares are available for trading.
Stock saw a price change of -1.26% in past 5 days and over the past one month there was a price change of -9.32%. Year-to-date (YTD), IMVT shares are showing a performance of -23.78% which decreased to -38.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $17.65 but also hit the highest price of $35.97 during that period. The average intraday trading volume for Immunovant Inc shares is 1.22 million. The stock is currently trading -4.11% below its 20-day simple moving average (SMA20), while that difference is down -10.61% for SMA50 and it goes to -29.16% lower than SMA200.
Immunovant Inc (NASDAQ: IMVT) currently have 147.20M outstanding shares and institutions hold larger chunk of about 47.38% of that.
The stock has a current market capitalization of $3.21B and its 3Y-monthly beta is at 0.77. It has posted earnings per share of -$2.62 in the same period. It has Quick Ratio of 6.04 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMVT, volatility over the week remained 8.09% while standing at 5.84% over the month.
Stock’s fiscal year EPS is expected to drop by -49.95% while it is estimated to decrease by -8.28% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on March 03, 2025 offering a Hold rating for the stock and assigned a target price of $20 to it. On October 10, 2024, Raymond James Resumed their recommendations, while on October 09, 2024, Oppenheimer Reiterated their ratings for the stock with a price target of $53. Stock get an Outperform rating from Oppenheimer on March 28, 2024.
